BACKGROUND: @entity2816 has been reported to have antitumor activity for treating metastatic @entity157 ( @entity157 ). We evaluated the safety and efficacy of using @entity2816 for treating selected @entity1 with unresectable or metastatic @entity157 , and their disease was refractory to systemic chemotherapy. METHODS: Eight @entity1 with measurable and metastatic @entity157 that had progressed with prior systemic chemotherapy and who desired further active therapy were enrolled in this study. @entity2816 was given orally at bedtime and it was started at 200 mg/day with no further dose escalation. The response was measured at 2-month intervals. RESULTS: The median age was 44 years (range: 34-52 years) and all the @entity1 had received @entity632 -based systemic chemotherapy prior to their enrollment. Each @entity1 received @entity2816 for a median of 152 days (range: 5-422 days). One partial response was observed (12.5%, 95% CI; 0-42%) along with 4 cases of stable diseases. The most commonly encountered @entity137 was somnolence; grade 3 somnolence was noted for one @entity1 , which led to treatment discontinuation. Skin rash was observed in one responding @entity1 . CONCLUSIONS: The results indicate that @entity2816 may feasibly offer disease stabilization to metastatic @entity157 @entity1 . Further dose escalation of @entity2816 , or its combination with other chemotherapeutic agents, may be of interest and this should be investigated for treating @entity1 with metastatic @entity157 .

@entity2816 for treating metastatic XXXX : a pilot study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['Thalidomide', 'thalidomide'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
